The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03273231

Enrollment

100

Registered

2017-09-06

Start date

2017-09-01

Completion date

2020-07-31

Last updated

2019-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Systemic inflammation caused by surgery may aggravate immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. ketamine, a N-methyl-D-asparate receptor antangonist, has anti-inflammatory activity and opioid-sparing effect. This study investigate the effect of intraopertaive ketamine administration on immune function in patients undergoing laparoscopic colorectal cancer resection.

Interventions

DRUGKetamine

Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.

DRUGSaline

0.9% saline solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patient between 20 and 80 of age with ASA physical status Ⅰ-Ⅲ * patient scheduled for laparoscopic colorectal cancer resection

Exclusion criteria

* ASA physical status Ⅳ * severe hepatorenal disease * heart failure * infection * increased intracranial pressure, seizure * preoperative chemotherapy * immune or endocrine disease * metastasis to other organ * problem with communication * pregnancy * body mass index \> 35 kg/m2

Design outcomes

Primary

Measure	Time frame	Description
natural killer cell cytotoxicity	Baseline	Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).

Secondary

Measure	Time frame	Description
proinflammatory cytokine	Baseline	Inflammtory response is assesssed by measuring levels of proinflammtory cytokines.
recurrence	1 year after surgery	Cancer recurrence is evaluated 1 year after surgery.
metastasis	1 year after surgery	Cancer metastasis is evaluated 1 year after surgery.

Countries

South Korea

Contacts

Primary ContactJin Sun Cho, MD

chjs0214@yuhs.ac82-2-2228-5448

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026